Taconic Biosciences News

Taconic Biosciences News is your source for current and relevant news on how animal models are being used to drive drug discovery. Use the links below to explore exciting announcements from Taconic via Press Releases, Taconic’s press coverage in Publications and Media, and critical scientific insights within Industry News.

The Brain: The Decade Ahead

PharmaVOICE features Taconic because of their expertise on CNS disorders and research: "The three-pound organ -- made up of more than 100 billion nerves -- that serves as the center of the nervous system is one of the most complex parts of the human body. Only recently have researchers and scientists begun to understand the brain and what can go wrong. This special forum kicks off a...

Read More

GEN Roundup: Optimizing Your ADME/Tox Operations

Genetic Engineering & Biotechnology specifies best practices for improving ADME/Tox efforts: "Early-Drug Screening Is Due For Review - Before a new prescription medicine gains marketing approval, it typically goes through a development process that lasts at least a decade. Moreover, according to the Tufts Center for the Study of Drug Development, the costs can exceed $2.5 billion." Read the complete article at: genengnews.com...

Read More

The increasing impact of precision research models on drug discovery and development

Drug Discovery World features Taconic Biosciences outlining the advancements made of genetically engineered models: "In a Challenges and Opportunities report issued by the US Food and Drug Administration (FDA), it was noted that the inability to predict lack of effectiveness and safety problems before human testing or early in clinical trials dramatically escalates costs of drug development. According to the FDA, drug developers could save $100 million...

Read More

Tumor Models Bridge Mouse-Human Gap

Genetic Engineering & Biotechnology details trends in animal and humanized models available at Taconic: "Revamped Allograft and Innovative Xenograft Models Can Reduce the Risks of Late-Stage Clinical Trials and Increase the Odds of Translational Success - Precision medicine is all about the two T's—targets and treatments—targets that emerge from analyses of patient-specific information, and treatments that hit these targets. Both T's, however, pose difficulties. All too often,...

Read More

New Guidelines Involve the Testing Done on Animal Models

Genetic Engineering & Biotechnology News details safety testing done with Taconic models: "Prior to obtaining regulatory approval for use in humans, novel pharmaceutical drugs require extensive safety testing. Guidelines regarding testing strategies are issued by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), an agreement established in 1991 between the regulatory authorities in the United States, European Community (EC),...

Read More

Taconic Biosciences Funds Custom Vici Syndrome Mouse Model Development and Breeding

ALN Mag features Taconic's Jim Vitale who discusses funding the development and breeding of custom mouse models to study Vici Syndrome: "Hosted by the Rare Genomics Institute, the Rare Disease Science Challenge is an annual event in which industry sponsors donate services to accelerate rare disease research. This is the second year that Taconic has participated in this challenge. "We see this as an opportunity for Taconic...

Read More

Taconic Biosciences to Fund Custom Model Development and Breeding to Support Vici Syndrome Research

Taconic Awards Integrated Solution as Sponsor of Rare Disease Challenge Hudson, NY - August 24, 2015 - Taconic Biosciences, a leading provider of genetically modified models and services to researchers worldwide, announced it will fund the development and breeding of a custom mouse model to study Vici Syndrome. Taconic is donating the work as a Corporate Sponsor and Ultimate Technology Sponsor of the 2015 Rare Disease Science...

Read More

Stem Cell Special Report: Germlines and gene-editing

DDNews features Taconic Biosciences in this write-up due to their knowledge of gene-editing technology: "Early this year, Junjiu Huang and colleagues in China triggered a cascade of controversy when they decided to apply gene-editing technologies to human embryos, methods that had been extensively applied to embryos of other species. As they stated in the abstract of their paper in Protein & Cell, they wanted to better understand...

Read More

The Human Touch

The Scientist discusses humanized mice used at Taconic Biosciences: "In 1993, National Institutes of Health (NIH) researchers gave Eli Lilly's promising experimental hepatitis B drug fialuridine to 15 patients as part of a small Phase 2 trial. It did not go well. Five of the patients died; two more required emergency liver transplants. Fialuridine had undergone toxicity testing in mice, rats, dogs, and even nonhuman primates with...

Read More

Rare Diseases: Research, Development, and Commercialization

PharmaVOICE speaks of advancements made in researching rare diseases: "In the past few years, significant progress has been made in rare diseases; in 2014, orphan drugs constituted 17 of the 41 new molecular entities approved by the Food and Drug Administration. An average of 140 drugs have been designated as orphan drugs by the FDA each year over the past decade, compared with 64 in the previous...

Read More